Virta Health
Dr. Stephen Phinney: Are there benefits of fasting, including autophagy and apoptosis?
updated
About Virta
Virta Health is the leader in type 2 diabetes reversal and is creating a new standard in medical care for people living with type 2 diabetes, prediabetes, or obesity. Our virtual approach combines personalized nutrition therapy with continuous provider-led support to empower members to eliminate medications, lose weight, and take back their lives. Virta has earned the trust of the nation’s largest organizations, including Humana, AutoZone, and Blue Shield of California. We also deliver industry-leading cost savings of nearly $5,000 per patient per year while putting our fees at risk based on health outcomes. To learn more, visit https://www.virtahealth.com.
About Virta
Virta Health is the leader in type 2 diabetes reversal and is creating a new standard in medical care for people living with type 2 diabetes, prediabetes, or obesity. Our virtual approach combines personalized nutrition therapy with continuous provider-led support to empower members to eliminate medications, lose weight, and take back their lives. Virta has earned the trust of the nation’s largest organizations, including Humana, AutoZone, and Blue Shield of California. We also deliver industry-leading cost savings of nearly $5,000 per patient per year while putting our fees at risk based on health outcomes. To learn more, visit www.virtahealth.com.
About Virta
Virta Health is the leader in type 2 diabetes reversal and is creating a new standard in medical care for people living with type 2 diabetes, prediabetes, or obesity. Our virtual approach combines personalized nutrition therapy with continuous provider-led support to empower members to eliminate medications, lose weight, and take back their lives. Virta has earned the trust of the nation’s largest organizations, including Humana, AutoZone, and Blue Shield of California. We also deliver industry-leading cost savings of nearly $5,000 per patient per year while putting our fees at risk based on health outcomes. To learn more, visit www.virtahealth.com.
- Orriel Richardson (Vice President of Health Equity and Policy, Morgan Health)
- Katherine Bobroske (Vice President of Data Science, Morgan Health)
- Cybele Bjorklund (SVP of Policy and Government Affairs, Virta Health)
Description:
More than 150 million Americans depend on employer-sponsored insurance (ESI) for their health care, but the health outcomes of ESI enrollees has not been well understood given historical data gaps and limitations in analyzing health outcomes across race, ethnicity and income.
In late 2022, Morgan Health and NORC published a first-of-its-kind data analysis leveraging three nationally-representative, public surveys and national vital statistics records. Despite the perceptions of robustness of coverage among those with ESI, the results showed a sobering view of the health outcomes and affordability challenges of America’s largest insurance market.
“These findings are a wake-up call for business leaders on the severe health disparities that exist across the country’s workforce,” said Dan Mendelson, Morgan Health CEO. “The business community has a responsibility to understand and recognize these disparities, and more importantly, act to eliminate them. This will require active engagement with health plans and providers to close gaps and improve health outcomes.”
Watch this webinar for a deep dive of the breakthrough findings of this report, followed by a roundtable discussion with Morgan Health experts.
Date: Oct 13, 2022
Speakers:
+ Dorothy Gemmell (President, DKG Solutions)
+ Dr. Gina Conflitti (President, Platinum Health Consulting)
+ Dr. David Hanekom (SVP & Chief Medical Officer, Quartz Health Solutions)
+ Dr. Rahul Rajkumar (President & CEO, Accompany Health)
+ Dr. Sachin Jain (President & CEO, SCAN Group & SCAN Health Plan)
Date: Oct 13, 2022
Speakers:
+ Ron Harrison (VP of Business Development, Mark Cuban CostPlus Drug Company)
+ Dr. Sharon Jhawar (Chief Pharmacy Officer, SCAN Health)
+ Dr. William Shrank (Senior Advisor, Humana)
+ Dr. Chantell Sell (National Clinical Pharmacy Lead, Willis Towers Watson)
Date: Oct 13, 2022
Speakers:
+ Dr. Susan Kirsh (Acting Deputy Assistant Under Secretary for Health for DEAN, Veterans Health Administration)
+ Dr. Sree Chaguturu (Executive Vice President and Chief Medical Officer, CVS Health)
+ Kevin Kumler (President, Virta Health)
Date: Oct 12, 2022
Speakers:
+ Dr. Nora Dennis (Lead Medical Director, Behavioral Health & Health Equity, Blue Cross NC)
+ Benjamin Jackson (VP, HR Technology & Analytics, AT&T)
+ Joanna Balogh-Reynolds (VP, Clinical Consultant and National Well-being Solutions Leader, Segal)
+ Dr. Darrell Gray (Chief Health Equity Officer, Elevance Health)
Date: Oct 12, 2022
Speakers:
+ Dr. Robert Groves (Chief Medical Officer, Banner|Aetna)
+ Dr. Josh Riff (Founder, EHIR; Included Health Communities)
+ Dr. Anthony Nguyen (Chief Clinical Officer, Elevance Health)
Date: Oct 12, 2022
Speakers:
+ Dr. Susan Fleischman (Chief Medical Officer, Blue Shield California)
+ Dr. Dora Hughes (Chief Medical Officer, The CMS Innovation Center at the Centers for Medicare and Medicaid Services)
+ Sami Inkinen (CEO, Virta Health)
In this webinar, Al Lewis and Validation Institute share:
1. Why evaluating vendors via rigorous validation is important for your bottom line
2. How to use the new gold standard in validation to evaluate vendors
In this webinar, we brought together medical leaders, research scientists, and patients to share:
- A clinical overview of the latest research on diabetes reversal’s impact on whole person health
- A real world perspective from the CMO of Dean Health—his top advice for other health plan and benefits leaders
- An interview with a patient who reversed his diabetes and transformed his health
Speakers:
- Kevin Eichhorn, MD, Chief Medical Officer, Dean Health Plan
- Amy McKenzie, Senior Director of Research and Innovation, Virta Health
- Andy Riddle, Virta Patient
- Jonathan Pearlstein, Senior Director, Enterprise Marketing, Virta Health
Speakers:
+ Jonathan Pearlstein, Senior Director, Enterprise Marketing, Virta Health
+ Kelly Close, Founder & President, Close Concerns; Diabetes & PreD Advocate
+ Richard Wood, CEO, dQ&A - The Diabetes Research Company
+ Jackie Tait, Senior Analyst, dQ&A - The Diabetes Research Company
+ Abbie Davis, Ed.D., Virta Patient, Professional in Higher Education
Description:
Did you know that 78% of type 2 diabetes patients are unaware of “reversal”...but once they know, 87% are motivated to try it?
In December 2021, we partnered with The Diabetes Research Company to survey 1,000 people living with type 2 diabetes about their views and opinions on diabetes reversal. For the first time ever, we will unveil our findings in the area – specifically we’ll dive into patient receptivity, readiness, and awareness of the three treatment options that lead to diabetes remission: bariatric surgery, extreme low-calorie diets, and low-carb high-fat diets.
In addition, join us in welcoming special guest Kelly Close as she shares learning lessons from advocating diabetes wellness to benefits leaders, and a Virta patient to share their first-hand experience with Virta’s diabetes reversal treatment.
Featuring Speakers:
+ Tricia Neuman, SVP of Medicare Policy, Kaiser Family Foundation
+ Mark Miller, EVP of Healthcare, Arnold Ventures; Former ED of MedPAC
+ Cybele Bjorklund, SVP of Policy, Virta Health
For years, US policymakers from both parties have worked to improve affordability of prescription drugs with little success. Insulin in particular has been a key area of focus, as insulin prices have skyrocketed over the last decade. President Biden’s Build Back Better (BBB) legislation would make significant changes across a number of key areas, but its outlook is far from clear.
Both the public and private sector have made numerous attempts to curb rising prescription drug costs with efforts ranging from policy proposals to permit Medicare to negotiate lower prices, and Express Script’s price caps for insulin co-payments.
In this webinar, a panel of top policy experts to decode the latest chatter and trends on drug pricing as we investigate the potential impact on health plan and employer benefits and spending. Topic discussed include:
+ State of the union on drug pricing initiatives, both BBB and potential for administrative action
+ Strategic implications for employers and health plans
+ What’s next—additional policy gaps and opportunities for diabetes reversal
Speakers:
Sharon Jhawar (Chief Pharmacy Officer, SCAN Health)
Robert Ratner (Chief Medical Officer, Virta Health)
Cybele Bjorklund (Senior Vice President of Policy, Virta Health)
Diabetes drugs are one of the costliest for health plans, and a recent KFF report showed that they accounted for up 7 out of 22 top drugs whose prices outpaced inflation. How are health plans responding? Each day, more health plans are looking for innovative solutions (outside of traditional diabetes management) to combat the insulin cost crisis. We were honored to have the Chief Pharmacy Officer at SCAN Health join us and share how they’re tackling insulin and Rx affordability for their members, and specifically, reversing type 2 diabetes in their population.
+ The COVID Vaccine Mandate - What Employers Should Know
+ The Economy, Jobs, and Social Determinants of Health
+ New Approaches to Chronic Disease Including Diabetes and Obesity
Dr. Emanuel is the Vice Provost for Global Initiatives, the Diane v.S. Levy and Robert M. Levy University Professor at the University of Pennsylvania. He is also a Special Advisor to the Director General of the World Health Organization, the founding chair of the Department of Bioethics at the National Institutes of Health, and also served as a Special Advisor on Health Policy to the Director of the Office of Management and Budget and National Economic Council.
In November 2020, President Biden named Dr. Emanuel to be one of the 16 members of the COVID-19 Advisory Board. And most recently, he organized an effort backed by over 50 medical groups for healthcare employers to require the COVID-19 vaccine for their employees.
On Virta, Pastor Phillip reduced the need for a medications, lost 270 pounds, regained his energy. Now, people in his congregation look to him for health advice. Something that still makes him laugh.
The efforts to better define diabetes remission comes on the heels of heightened focus on diabetes remission. That’s because achieving diabetes remission holds enormous value for payers and patients alike. It also represents a completely different treatment outcome compared to traditional forms of diabetes management, which focus on blood glucose control through high-cost medications.
There are multiple well-known clinical strategies for achieving diabetes remission, ranging from bariatric surgery, to calorie restriction, to low carbohydrate diets. In this webinar, we address these specific interventions, as well as broader topics around the definition and need for increased focus and investment in diabetes remission.
In this webinar you will hear directly from the world’s leading health economists and analytics experts, as they weigh in on the new gold standards for ROI evaluation and benefits design. Virta experts will also dive into our latest breakthrough outcomes - $425 gross savings PPPM, one of the highest published PPPM savings to date across the digital health landscape.
Michael Chernew, PhD, an economist and professor of health care policy at Harvard Medical School. He studies strategies to reduce health care spending and improve health outcomes and currently serves as chair of MedPAC (Medicare Payment Advisory Commission) and served as chair of the Harvard Benefits committee for 9 years.
With Virta, you can make a difference for your members and employees. Choose Virta, and join the hundreds of employers, health plans, and health systems who are transforming lives today.
Learn more about reversing diabetes at virtahealth.com
+ Gregory Burrell, MD, VP Clinical Solutions, Associate Chief Medical Officer, Accolade
+ Nathan Gregory, SPHR, SHRM-SCP, Assistant Director of Human Resources, City of Fort Worth
+ Trent Myers, National VP Sales & Alliances, Virta Health
As employers across the nation begin to roll out their return-to-work policies, are there segments of your population, whose voices have gone unheard, in particular those who are most vulnerable or underserved? A one-size-fits-all approach certainly will be problematic. Without careful consideration, it may widen health disparities for team members with chronic conditions like type 2 diabetes, who depend on their routines to stay healthy.
How should benefits leaders develop an inclusive and personalized healthcare strategy, so that no one is left behind?
Commercial, HR, clinical executives at Accolade, City of Fort Worth, and Virta Health talk about how they've structured a unique health & wellness partnership model to prepare for the challenges of the future hybrid workplace.
Learn more about Virta Health at virtahealth.com
Follow us at:
twitter.com/virtahealth
facebook.com/virtahealth
linkedin.com/company/virta-health
+ Chantell Sell, PharmD, National Pharmacy Clinical Lead, Willis Towers Watson
+ Sami Inkinen, MSc, MBA, CEO and Co-Founder, Virta Health
+ Hassan Azar, JD, MBA, MPH, MHA, MA, VP Global Benefits, Jones Lang LaSalle
Obesity rates continue to soar, but earlier this month we were met with intriguing news. On June 4th, the FDA approved a new weight-loss drug in which the outcomes which were described as “breakthrough” and “game-changing” Patients on average lost 33.7 pounds after 68 weeks, more than 1.5x higher than the next best obesity drug. Experts predict the record-breaking efficacy rates could unleash the obesity drug market, which has historically lingered at a low of less than 1% penetration rate.
Despite what looks like a promising turn of events at the surface, there is growing concern that we’re at a tipping point for a healthcare cost crisis. With an estimated list price per patient of $15,600 this newly approved GLP-1 could take a huge hit on employers and payers who are already struggling to control growing medication and healthcare costs.
Learn more about Virta Health at virtahealth.com
Follow us at:
twitter.com/virtahealth
facebook.com/virtahealth
linkedin.com/company/virta-health
Learn more about Virta Health at virtahealth.com
Follow us at:
twitter.com/virtahealth
facebook.com/virtahealth
linkedin.com/company/virta-health
+ Setu Vora, MD. Chief Medical Officer, Pequot Health Care, MPTN
+ Trent Myers, VP Sales and Alliances, Virta Health
+ Heather, Virta Patient, Employee of Mashantucket Pequot Tribal Nation
Description:
Telemedicine is booming, but many still see it as exclusive to the Silicon Valley elite. The typical digital health consumer is often painted as Apple-watch lovers, middle-aged and high-income earners.
But early adopters in rural America are proving otherwise. A growing number of success stories are showing the enormous, untapped potential for digital health’s impact in rural communities.
One year ago, the Mashantucket Pequot Tribe embarked on a journey to reverse diabetes in their community. What seemed like an impossible journey (given the disproportionately high prevalence of type 2 diabetes in Native Americans) turned out to be a groundbreaking success. While other diabetes solutions have failed to make any sizable impact in this population, they were able to see transformative success with Virta.
In a case study format, we will examine the building blocks of how they were able to unlock digital health adoption.
Learn more about Virta Health at virtahealth.com
Follow us at:
twitter.com/virtahealth
facebook.com/virtahealth
linkedin.com/company/virta-health
+ Bob Kocher, MD (Partner, Venrock; Former Health Policy Advisor to President Obama)
+ Rahul Rajkumar, MD, JD (Chief Operating Officer at Optum UnitedHealth)
+ Robert Ratner, MD, FACP, FACe (Former Chief Medical Officer at American Diabetes Association, Chief Medical Officer at Virta Health)
Description:
COVID-19 spurred a wave of telemedicine adoption, but how much is just hype, and how much will truly deliver sustained transformation to healthcare? What changes will actually endure after the dust from the pandemic settles?
Listen in on a high-level strategic discussion designed for health plans, employers, and health systems leaders.
+ Trends in health IT investment in Silicon Valley and how to stay ahead of them
+ Health policy implications of President Joe Biden and Democratic control
+ Strategic imperatives for value-based care and chronic disease strategy in a virtual world
+ Changing the diabetes care paradigm from management to reversal
Dr. Berwick was previously the head of the Centers for Medicare and Medicaid Services, nominated by President Barack Obama, and CEO of the Institute for Healthcare Improvement. Over the course of his career, he pioneered several bold initiatives to transform healthcare, including the 100,000 Lives Campaign, and 5 Million Lives Campaign.
In this webinar we discuss:
+ The top health policy changes on the Biden Administration’s agenda
+ How payers, providers, and employers can prepare for upcoming changes
+ How this will impact patients, particularly Medicare, Medicaid, and patients living with diabetes
Speakers:
+ Don Berwick, MD, MPP (Former Administrator, Centers for Medicare and Medicaid Services)
+ Robert Ratner, MD, FACP, FACE (Chief Medical Officer, Virta Health; Former Chief Medical Officer of the American Diabetes Association)
+ Sami Inkinen, MBA, MSc (CEO & Co-Founder, Virta Health)
Anthony Masso is the former president and CEO of Consortium Health Plans, run by 20 Blue Cross Blue Shield plans focused on growing national account market share. His deep experiences with Blue plans and his CEO relationships over the years serve the companies he represents today.
He has served on the boards of more than 15 companies ranging from managed care payers, physician groups, private equity purchases, public companies, and venture-backed startups. He was SVP of the Health Insurance Association of America, where he planned and implemented a major transformation of indemnity insurers into managed care networks. As regional president of Aetna Health Plans, he led East Coast operations for HMO and POS plans. Tony also served as a senior executive with HHS, and as a legislative aide for the U.S. Senate. He was operations officer of smallpox eradication at CDC and a special assistant to the Peace Corps. Tony has lived in Africa and Latin America for years on assignments.
His experiences includes being Chairman of the Kauffman Foundation Scholars Program and special advisor to the CEO. He also served on staff of the U.S. Senate and advisor to the Director of NIH.
He recently served on the boards of Health Plan Services, Zenith Health, Access Health, and Catamaran Corp before their successful exit sales. He is an executive advisor and board member to Water Street Health Partners and General Atlantic where he serves to grow companies like Evicore, MedExpress, Health, New Century, Breg, Landmark, and others. He currently serves as senior advisor to Carecentrix, Sharecare, Emerging Therapies Solutions, and Clarify Health Solutions. Most recently he joined Virta as Strategic Advisor.
Read more here: virtahealth.com/people/anthony-masso
Speakers:
+ Alan Moses, MD (Former CMO, Novo Nordisk)
+ Robert Ratner, MD, FACP, FACE (CMO, Virta Health; Former CMO, American Diabetes Association)
+ Shantanu Nundy, MD, MBA (CMO, Accolade)
+ Sami Inkinen, MSc, MBA (CEO Virta Health)
Topics discussed include:
+ 5 predictions for diabetes care
+ Updated pharmacological approaches for T2D
+ Updated non-pharmacological approaches for T2D
+ Promising new care delivery models for diabetes
+ Kara Speer, MPH (Director of Health Management, Willis Towers Watson)
+ Chris Rukus (Benefits Director at Honeywell, Formerly at Sealed Air)
+ Jeff Stanley, MD (Medical Director, Virta Health)
+ Thai & Robert (Virta Patients)
+ Britt Volk (Clinical Expert, Virta Health)
The diabetes epidemic continues to grow at a staggering rate, despite the billions of dollars invested in drug development. Ironically, the "silver bullet" won't be the next new pill. Rather, it's moving patients off their medications by addressing the root cause of type 2 diabetes. This concept is baked into the core of Virta's care model.
In 2019 Virta rolled out its diabetes reversal treatment to 7+ employers. On this webinar, we'll showcase this cohort's results for the first time.
On this webinar you will hear from consultant Kara Speer, alongside employers who participated in the pilot, clinical leadership from Virta, and actual patients who benefited from the treatment. Topics covered:
+ The diabetes vendor landscape
+ Frameworks for designing pilot cohorts
+ Clinical outcomes from the cohort
+ Voices from employers and patients
Fast forward to 2020, clinical outcomes are emerging across the nation. Tune in to hear two visionary leaders speak on the promise and rise of this revolutionary approach, and what it will mean for your business.
Steve Martin, former CEO of Blue Cross and Blue Shield Nebraska and founder of Prime Therapeutics, will share his personal journey running Nebraska's largest health plan, to reversing his own diabetes without the use of medication or surgery.
Dr. Bob Ratner, former Chief Science and Medical Officer of the American Diabetes Association with over 35 years of medical expertise, will decode the newly released 2020 Standards of Care, and the latest scientific research around COVID-19 and diabetes. Dr. Ratner will also reflect on his experience leading the NIH Diabetes Prevention Program for two decades. His discoveries have stood the test of time—they are just as relevant (if not more so) today, as the pandemic continues to prove the growing need to shift from diabetes management, to prevention and reversal.


